the osd facility relocation groundbreaking ceremony of eisai china inc. (hereinafter referred to as “eisai china”) was held at suzhou industrial park on the morning of may 31, 2016. the leaders of the japanese consulate general in shanghai, jiangsu provincial food and drug administration, suzhou municipal government, management committee of suzhou industrial park, suzhou municipal food and drug administration, eisai co., ltd., and eisai china attended the groundbreaking ceremony.
osd facility relocation groundbreaking ceremony of eisai china inc.
dr. haruo naito, ceo of eisai co., ltd.
dr. haruo naito, ceo of eisai co., ltd., said in his speech, “it has been 20 years since we entered suzhou industrial park in 1996. we have witnessed the rapid and healthy development of suzhou as well as china, and our business in china is growing constantly. it is estimated that our sales volume in china will reach 3 billion yuan this year. eisai will uphold the operation concept of “hhc (human health care)”, put the interests of patients and their families in the first place, and make contributions to the improvement of their well-being. meanwhile, we will regard compliance (compliance with laws, regulations and ethics) as the most fundamental code of conduct in our day-to-day business, and be devoted to the fulfillment of our social responsibilities”.
design sketch of the new facility of suzhou plant of eisai china
this solid preparation facility covers a floor area of 31,000 square meters, including a building area of 23,000 square meters, and its designed production capacity will reach 3 billion preparation tablets /year and 5 billion package tablets /year, according to sources. the facility design will place stress on energy saving, and the international plant will be designed and built according to chinese gmp and internationally recognized gmp. in the future, the base will supply high-quality products produced by suzhou plant of eisai china to other asian countries and regions in addition to the chinese market. it is estimated that the new facility will be completed in october 2017, and may be officially put into operation in june 2018. currently, the phase i logistics warehouse and injection production workshop have been completed and put into operation. after completion of the solid preparation facility, suzhou plant of eisai china will be relocated to 168 xingpu road of industrial park from 32 baiyu road of industrial park.
1. eisai co., ltd.
eisai co. ltd. (japanese name: エーザイ株 式 会 社, chinese name: 卫材株式会社, hereinafter referred to as “eisai”) is a multinational company dedicated to the research and development of pharmaceuticals. founded in 1941, it is headquartered in tokyo, japan, and has three major institutions, namely tsukuba institute in japan, boston institute in the u.s., and london institute in britain. its foreign branches, subsidiaries and plants are all over europe, america, and asian countries and regions.
by 2015, the company had 10,183 employees worldwide, its sales volume reached 548.5 billion japanese yen (about 5 billion u.s. dollars), and 20% of such sales volume was used for development investment. eisai covers five major regions, namely japan, america, europe, asia and china. it is dedicated to the research and development of neurology, gastroenterology and oncology.
2016 marks the 25th anniversary of eisai’s entry into the chinese market, as well as the 20th anniversary of the establishment of eisai china. in addition to japan, china alone is regarded as a target region. currently, its companies in china include eisai china inc. and its branches, eisai china holdings ltd., eisai (suzhou) trading co., ltd., and eisai (liaoning) pharmaceutical co., ltd.
2. eisai china inc.
eisai china inc. is a pharmaceutical company owned solely by eisai co., ltd. founded in march 1996 and with a gross investment of 230 million u.s. dollars, the company is located at 32 baiyu road at suzhou industrial park, and has set up 10 branches in big cities.
currently, eisai sells more than ten types of medicines in china, and such medicines are mainly used for the central nervous system, digestive and hepatic diseases, endocrinology and orthopaedics. all the products that it produces are for domestic sales. after 20 years of steady development, the number of employees of the company has reached 1,849, the sales volume was 2.6 billion yuan, and the total tax payment was 592 million yuan by the end of 2015. eisai china has always been a key tax-payer enterprise in suzhou since 2001. the average growth rate of its yearly sales volume in the past 5 years reached 20%, and it is estimated that its sales volume in 2016 will reach 3 billion yuan.
as part of its global manufacturing system, suzhou plant of eisai carries out in-situ production of solid preparations and subpackaged production of imported products. in the early stage of development, suzhou plant was located in suzhou industrial park, covered an area of 25,000 square meters, and was equipped with the most advanced machines. in 2005, eisai added investment of 55 million u.s. dollars for construction of the phase-ii facility in order to increase its production capacity. in order to maintain its business development in china, eisai added investment of 120 million u.s. dollars in 2010, bought a piece of new land in suzhou industrial park to build a new facility for development, production and logistics. this new facility will become a global innovation center of eisai in the future. currently, the logistics warehouse and injection production workshop in the new facility have been completed and put into operation.
3. eisai china holdings ltd.
eisai established eisai china holdings ltd. at suzhou industrial park in november 2014, with a registered capital of 108.54 million u.s. dollars. the company successfully bought a domestic pharmaceutical enterprise in december 2015, and established eisai (liaoning) pharmaceutical co., ltd., with a registered capital of 50 million yuan.
4. eisai (suzhou) trading co., ltd.
eisai established eisai (suzhou) trading co., ltd. at the comprehensive bonded zone of the park in 2010, with a registered capital of 70 million yuan and mainly for wholesale of medicines. the company carried out business successfully, and its sales volume reached 285 million yuan in 2015.
5. eisai (liaoning) pharmaceutical co., ltd.
eisai china holdings ltd. signed an agreement with liaoning tianyi biological pharmaceuticals co., ltd. in november 2015, and eisai china investment co., ltd. purchased 100% of the shares of liaoning tianyi biological pharmaceutical co., ltd. through this acquisition, eisai will enter the generic pharmaceutical business in china in addition to expanding its existing business focused on new medicines. by further strengthening its business platform foundation established over 25 years of doing business in china and providing a stable supply of high quality generic pharmaceuticals, eisai will be able to fulfill an even wider range of medical needs in china.